A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Journal of Hematology & Oncology

Sandra Horning⁴  Brad S Kahl⁸  Jill Kolesar⁸  Randy D Gascoyne³  Taral Patel⁵  David King⁶  Ronald S Go⁹  Selina M Luger¹  Hailun Li⁷  Daniel R Greenwald² 

[1] University of Pennsylvania, Philadelphia, PA, USA;Cancer Center of Santa Barbara, 540 West Pueblo St, Santa Barbara, CA 93105, USA;British Columbia Cancer Agency, Vancouver, Canada;Roche-Genentech, South San Francisco, CA, USA;Columbus CCOP, Columbus, OH, USA;Health One Mercy Hospital, Coon Rapids, MN, USA;Dana Farber Cancer Institute, Boston, Massachusetts, USA;University of Wisconsin, Madison, WI, USA;Gundersen Lutheran Health System, La Crosse, WI, USA

关键词: Sorafenib;    MAP kinase signaling;    Diffuse large B cell lymphoma;    NHL;   

Others  :  804635
DOI  :  10.1186/1756-8722-6-46

 received in 2013-03-22, accepted in 2013-05-07,  发布年份 2013

【 摘 要 】

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43–9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1–12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 – 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 – 5 months). Median overall survival (OS) was 9 months (90% CI, 5 – 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

【 授权许可】

   
2013 Greenwald et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Dalla-Favera R, Gaidano G: Lymphomas. In Principles and Practice of Oncology. Edited by Da Vita VT. Philadelphia: Lippincott Williams & Wilkins; 2001:2215-2231.
• [2]Philip T, Guglielmi C, Hagenbeek A, Somers R, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995, 333(23):1540-1545.
• [3]Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3(1):11-22.
• [4]Hunter T: Signaling 2000 - and Beyond. Cell 2000, 100:113.
• [5]Kobzdej M, Matuszyk J, Strzadala L: Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice. Leuk Res 2000, 24(1):33-38.
• [6]Kalas W, Kisielow P, Strzadala L: Inhibition of MEK induces fas expression and apoptosis in lymphomas overexpressing Ras. Leuk Lymphoma 2002, 43(7):1469-1474.
• [7]Ogasawara T, Yasuyama M, Kawauchi K: Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders. Int J Hematol 2003, 77(4):364-370. Erratum in: Int J Hematol. 2003
• [8]Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, et al.: Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001, 7(9):2898-2907.
• [9]Shlapatska LM, Berdova GG, Kovalevska LM, et al.: Signal transduction pathways in Burkitt’s lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin. Exp Oncol 2004, 26(3):210-216.
• [10]Jazirehi AR, Vega MI, Chatterjee D, et al.: Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res 2004, 64(19):7117-7126.
• [11]List AF: Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 2001, 6(Suppl 5):24-31.
• [12]Wang ES, et al.: Anti-VEGF receptor antibodies inhibit the growth of non-Hodgkin’s lymphoma and enhance the effects of chemotherapy or rituximab in lymphoma xenograft mouse models. Proc Am Soc Clin Oncol 2003, 22:210.
• [13]Gratzinger D, Zhao S, Marinelli RJ, et al.: Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007, 170(4):1362-1369.
• [14]Ganjoo K: Antiangiogenesis: A new approach to the treatment of lymphoma. Leuk Lymphoma 2007, 48:454-455.
• [15]Bollag G, Freeman S, Lyons JF, et al.: Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003, 4(12):1436-1441.
• [16]Lowinger TB, Riedl B, Dumas J, et al.: Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002, 8(25):2269-2278.
• [17]Wilhelm SM, Carter C, Tang L, et al.: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
• [18]Procopio G, Verzoni E, Testa I, et al.: Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol 2012, 4(6):303-313.
• [19]Zhang X, Yang XR, Huang XW, et al.: Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2012, 11(5):458-466.
• [20]Cheson BC, Horning SJ, Coiffer B, et al.: Report of international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999, 17:1244-1253.
• [21]Simon R: Optimal 2-stage designed for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
• [22]Hutson TE: Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Rev Anticancer Ther 2007, 7(9):1193-1202.
• [23]Guidetti A, Carlo-Stella C, Locatelli SL, et al.: Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol 2012, 158(1):108-119.
• [24]Buckstein R, Kuruvilla J, Chua N, Lee C, et al.: Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leuk Lymphoma 2011, 52(5):833-841.
• [25]Wiernik PH, Lossos IS, Tuscano JM, et al.: Lenalidomide monotherapy in relapsed or refractory aggressive Non-Hodgkin’s lymphoma. J Clin Oncol 2008, 26(30):4952-4957.
• [26]Advani RH, Buggy JJ, Sharman JP, et al.: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1):88-94.